11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy
- PMID: 31420008
- PMCID: PMC6698000
- DOI: 10.1186/s13075-019-1972-1
11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy
Abstract
Background: Despite their efficacy in the treatment of chronic inflammation, the prolonged application of therapeutic glucocorticoids (GCs) is limited by significant systemic side effects including glucocorticoid-induced osteoporosis (GIOP). 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a bi-directional enzyme that primarily activates GCs in vivo, regulating tissue-specific exposure to active GC. We aimed to determine the contribution of 11β-HSD1 to GIOP.
Methods: Wild type (WT) and 11β-HSD1 knockout (KO) mice were treated with corticosterone (100 μg/ml, 0.66% ethanol) or vehicle (0.66% ethanol) in drinking water over 4 weeks (six animals per group). Bone parameters were assessed by micro-CT, sub-micron absorption tomography and serum markers of bone metabolism. Osteoblast and osteoclast gene expression was assessed by quantitative RT-PCR.
Results: Wild type mice receiving corticosterone developed marked trabecular bone loss with reduced bone volume to tissue volume (BV/TV), trabecular thickness (Tb.Th) and trabecular number (Tb.N). Histomorphometric analysis revealed a dramatic reduction in osteoblast numbers. This was matched by a significant reduction in the serum marker of osteoblast bone formation P1NP and gene expression of the osteoblast markers Alp and Bglap. In contrast, 11β-HSD1 KO mice receiving corticosterone demonstrated almost complete protection from trabecular bone loss, with partial protection from the decrease in osteoblast numbers and markers of bone formation relative to WT counterparts receiving corticosterone.
Conclusions: This study demonstrates that 11β-HSD1 plays a critical role in GIOP, mediating GC suppression of anabolic bone formation and reduced bone volume secondary to a decrease in osteoblast numbers. This raises the intriguing possibility that therapeutic inhibitors of 11β-HSD1 may be effective in preventing GIOP in patients receiving therapeutic steroids.
Keywords: 11β-HSD1; Glucocorticoids; Osteoporosis; Trabecular bone.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures




Similar articles
-
11β-Hydroxysteroid Dehydrogenase Type 1 within Osteoclasts Mediates the Bone Protective Properties of Therapeutic Corticosteroids in Chronic Inflammation.Int J Mol Sci. 2022 Jun 30;23(13):7334. doi: 10.3390/ijms23137334. Int J Mol Sci. 2022. PMID: 35806338 Free PMC article.
-
Effect of 11β-HSD1 dehydrogenase activity on bone histomorphometry of glucocorticoid-induced osteoporotic male Sprague-Dawley rats.Singapore Med J. 2011 Nov;52(11):786-93. Singapore Med J. 2011. PMID: 22173247
-
11 Beta-hydroxysteroid dehydrogenase type 1 regulates synovitis, joint destruction, and systemic bone loss in chronic polyarthritis.J Autoimmun. 2018 Aug;92:104-113. doi: 10.1016/j.jaut.2018.05.010. Epub 2018 Jun 8. J Autoimmun. 2018. PMID: 29891135 Free PMC article.
-
11beta-hydroxysteroid dehydrogenase type 1 and obesity.Front Horm Res. 2008;36:146-164. doi: 10.1159/000115363. Front Horm Res. 2008. PMID: 18230901 Review.
-
Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)--a promising drug target for the treatment of metabolic syndrome.Curr Drug Targets Immune Endocr Metabol Disord. 2003 Dec;3(4):255-62. doi: 10.2174/1568008033340135. Curr Drug Targets Immune Endocr Metabol Disord. 2003. PMID: 14683456 Review.
Cited by
-
Pathogenic mechanisms of glucocorticoid-induced osteoporosis.Cytokine Growth Factor Rev. 2023 Apr;70:54-66. doi: 10.1016/j.cytogfr.2023.03.002. Epub 2023 Mar 5. Cytokine Growth Factor Rev. 2023. PMID: 36906448 Free PMC article. Review.
-
Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis.Front Neurol. 2023 Feb 1;14:1107474. doi: 10.3389/fneur.2023.1107474. eCollection 2023. Front Neurol. 2023. PMID: 36816559 Free PMC article.
-
11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.J Clin Endocrinol Metab. 2021 Jan 1;106(1):174-187. doi: 10.1210/clinem/dgaa766. J Clin Endocrinol Metab. 2021. PMID: 33098644 Free PMC article. Clinical Trial.
-
Deletion of Hsd11b1 suppresses caloric restriction-induced bone marrow adiposity in male but not female mice.J Endocrinol. 2024 Jun 24;262(2):e240072. doi: 10.1530/JOE-24-0072. Print 2024 Aug 1. J Endocrinol. 2024. PMID: 38805506 Free PMC article.
-
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.Neurology. 2024 Mar 12;102(5):e208112. doi: 10.1212/WNL.0000000000208112. Epub 2024 Feb 9. Neurology. 2024. PMID: 38335499 Free PMC article. Clinical Trial.
References
-
- Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253–259. doi: 10.1016/j.bone.2006.02.005. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous